BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37337881)

  • 1. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
    Eichenauer DA; Hartmann S
    Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
    Eichenauer DA; Fuchs M
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
    Eichenauer DA; Engert A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Curr Opin Oncol; 2021 Sep; 33(5):395-399. PubMed ID: 34224482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
    Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
    Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA; Varma G; Advani RH
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Binkley MS; Advani RH
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):471-476. PubMed ID: 37076366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.
    Sidda A; Naleid NK; Manu G; Graffeo V; Jamil MO
    J Investig Med High Impact Case Rep; 2022; 10():23247096221111767. PubMed ID: 35861500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular lymphocyte predominant Hodgkin lymphoma.
    Lee AI; LaCasce AS
    Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
    Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group.
    Klekawka T; Balwierz W; Brozyna A; Chaber R; Dadela-Urbanek A; Koltan A; Kwasnicka J; Mitura-Lesiuk M; Muszynska-Roslan K; Przybyszewski B; Ruranska I; Smalisz K; Mizia-Malarz A; Stachowicz-Stencel T; Stolarska M; Wziatek A; Zielezinska K; Skoczen S
    Pediatr Hematol Oncol; 2021 Oct; 38(7):609-619. PubMed ID: 33734010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
    Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
    Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte-Rich Classical Hodgkin Lymphoma. A Case with Difficulty in Distinguishing from Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Sakai J; Tanae K; Takahashi N; Nagata K; Yoshino T; Tamaru J; Niitsu N
    J Clin Exp Hematop; 2015; 55(1):23-8. PubMed ID: 26106003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
    Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
    Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.